Products with Anti-platelet aggregation bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4385 | Rutaecarpine |
| Rutaecarpine is an inhibitor of COX-2 with an IC50 value of 0.28 μM, and is also a potent inhibitor of CYP1A2. Rutaecarpine has anti-atherosclerosis, immunosuppressive, anti-inflammatory, gastroprotective, vasorelaxing, antihypertensive and anti-platelet effects. Rutaecarpine has positive inotropic and chronotropic effects on the guinea-pig isolated right atria, possible involvement of vanilloid receptors. Rutaecarpine may be useful in the prevention of ultraviolet A-induced photoaging, it inhibits ultraviolet A-induced reactive oxygen species generation, resulting in the enhanced expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human skin cells. | |
| BCN4443 | Xanthoxylin |
| Xanthoxyline has antispasmodic, fungistatic, antinociceptive and antioedematogenic activities. Xanthoxylin has inhibitory effect on blood platelet aggregation; it induces melanogenesis mainly via cAMP-mediated PKA activation, other signaling pathways may also play a role in xanthoxylin-induced melanogenesis. | |
| BCN4512 | Isoliquiritigenin |
| Isoliquiritigenin has hepatoprotective, chemopreventive, antitumor, vasorelaxant, anti-platelet, anti-allergic, antiviral, antioxidant and anti-inflammatory effects, it can induce growth inhibition and apoptosis through downregulating AA metabolic network and the deactivation of PI3K/Akt in human breast cancer. Isoliquiritigenin also has the ability to protect cells from AA+iron-induced H2O2 production and mitochondrial dysfunction, which is mediated with GSK3β phosphorylation downstream of AMPK. | |
| BCN4521 | Aristolactam AIIIa |
| 1. Aristolactam AIIIa has anti-tumor activity. 2. Aristolactam AIIIa was identified as a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD). 3. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid. | |
| BCN4558 | Denudatin B |
| 1. Denudatin B inhibits the aggregation and ATP release of washed rabbit platelets caused by platelet-activating factor (PAF) in a concentration-dependent manner. 2. Denudatin B has nonspecific antiplatelet action at high concentration by inhibiting phosphoinositides breakdown induced by collagen and thrombin. 3. Denudatin B relaxes vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated Ca2+ channels; its effect to increase cGMP may enhance the vasorelaxation. 4. Denudatin B shows potent 2, 2’-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) radical scavenging activity. | |
